Comparative Pharmacology
Head-to-head clinical analysis: CAPITAL AND CODEINE versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPITAL AND CODEINE versus METHADOSE.
CAPITAL AND CODEINE vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine, which acts as a mu-opioid receptor agonist, producing analgesia and CNS depression. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and pain perception.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Acetaminophen 300 mg plus codeine phosphate 30 mg orally every 4 hours as needed for pain; maximum acetaminophen 3000 mg/day, codeine 180 mg/day.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Codeine: 2.5-3 hours; Codeine-6-glucuronide: 2.5-3 hours; Morphine: 1.5-4.5 hours. Clinical context: In poor CYP2D6 metabolizers, half-life may be prolonged due to reduced clearance.
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Renal: 90% (codeine and metabolites, primarily as codeine-6-glucuronide and norcodeine), Biliary/Fecal: <10%
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist